- Select pulse oximetry technologies have proven to be effective in helping clinicians screen for CCHD.
- Signal Extraction Technology (SET) measure-through motion and low perfusion pulse oximetry21,23-25 (until another technology is proven to be equivalent). SET pulse oximetry is available in:
- Standalone monitors (Rad-5, Rad-57, Radical-7, Rad-87)
- Integrated in over 100 devices from over 50 companies including Atom, Drager, Fukuda Denshi, GE, Mindray, Nihon Koden, Philips, Spacelabs, and Welch Allyn.
- Consider utilizing a device that reduces operator induced-variability and improves efficiency by automating the screening steps, measurement selection, application of the measurements to the screening criteria chosen by the hospital, and categorization of the test as a positive or negative screen
- Eve® app on the Radical-7 (note this device CE Marked but has not received U.S. FDA 510k)
- Consider utilizing public health reporting systems for newborn screening
- Such as Oz® Systems newborn screening or automated reporting with Oz® BabyBundle
Metrics
Topic
Critical Congenital Heart Defects (CCHD)
The number of patients identified with CCHD through technology-enabled newborn screening. The rate is the reflection of the number of patients diagnosed with CCHD over the total number of infants screened.